Drug
In10018
In10018: highest development phase Phase 2, developed by InxMed (Shanghai) Co., Ltd.. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- InxMed (Shanghai) Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| IN10018 NCT06014528 | Phase 2 | Ovarian Cancer Recurrent |
| IN10018 NCT05994131 | Phase 1/2 | NSCLC |
| IN10018 NCT05827796 | Phase 1/2 | Pancreatic Cancer |
| IN10018 NCT06030258 | Phase 1/2 | Small Cell Lung Cancer Extensive Stage |
Latest
No recent events.
Follow In10018 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.